MassARRAY Multigene Screening Combined with LDL-C and sdLDL-C Detection for more Favorable Outcomes in type 2 Diabetes Mellitus Therapy

Abstract

Background: To determine the clinical value of multigene polymorphisms, LDL-C and sdLDL-C on T2DM therapy.Methods: In total, 352 T2DM patients before and after treatment and 48 healthy individuals were enrolled in this study. LDL-C and sdLDL-C were detected in 352 T2DM patients and 48 healthy individuals by Quantimetrix Lipoprint System. The 11 gene polymorphisms—HTR3B (rs2276307, A>G), APOE (rs7412, c.526C>T), APOE (rs429358, c.388T>C), CYP2C9*3 (rs1057910, c.1075A>C), KIF6 (rs20455, c.2155T>C), HMGCR (rs17238540, T>G), HMGCR (rs17244841, A>T), ABCB1 (rs2032582, c.2677G > T/A), HTR7 (rs1935349, C>T), SLCO1B1 (rs4149056, c.521T>C), and CETP (rs708272, G>A)—were screened in these 352 T2DM patients by the Agena Bioscience MassARRAY system before therapy.Results: Genetic polymorphisms associated with T2DM and statin effects in pretreatment patients were detected, then results showed that all 11 genes had heterozygous mutation, and 7 genes had homozygous mutation in 352 T2DM patients, more specifically reflected that these gene polymorphisms were common in Chinese T2DM patients. LDL-C and sdLDL-C were detected before and after treatment, sdLDL mainly existed in T2DM patients, and T2DM patients had higher mean levels of sdLDL-C than healthy people. After pharmacotherapy, the coincidence rates of decreases in LDL-C and sdLDL-C levels were 88.35% (311/352) and 84.09% (296/352), consistent with patients in remission.Conclusions: Gene polymorphisms related to pharmacotherapy were common in Chinese T2DM patients. And the expression of LDL-C and sdLDL-C was consistent with the T2DM disease course. Combined multigene screening before therapy and LDL-C and sdLDL-C detection before and after therapy could better assist T2DM treatment.